AWARD
R -- RECOVERY - Re-engineering Protocol Implementation and Development (RaPID) under Clinical Trials and Information Management Support
- Notice Date
- 3/30/2010
- Notice Type
- Award Notice
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Point of Contact
- John R. Manouelian, Phone: (301) 435-3813, Richard L Hartmann, Phone: (301) 496-8620
- E-Mail Address
-
manouelj@mail.nih.gov, hartmari@mail.nih.gov
(manouelj@mail.nih.gov, hartmari@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Award Number
- HHSN261200422005C-011
- Award Date
- 4/1/2010
- Awardee
- The EMMES Corporation (DUNS 096360284), 401 N. Washington Street, Suite 700, Rockville, Maryland 20850-0173, United States
- Award Amount
- $549,996
- Line Number
- Modification # 11
- Description
- <!-- /* Font Definitions */ @font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-alt:"Arial Rounded MT Bold"; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-1610611985 1073750139 0 0 159 0;} @font-face {font-family:Verdana; panose-1:2 11 6 4 3 5 4 4 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:536871559 0 0 0 415 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-parent:""; margin-top:0pt; margin-right:0pt; margin-bottom:10.0pt; margin-left:0pt; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:Calibri; mso-fareast-font-family:Calibri; mso-bidi-font-family:"Times New Roman";} @page Section1 {size:612.0pt 792.0pt; margin:72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.Section1 {page:Section1;} --> This action modifies an existing contract to provide funding for the Re-engineering Protocol Implementation and Development (RaPID) project. This contract provides information support, database administration, data management, statistical support, and operation office requirements in support of clinical trials. Support includes compilation, collation, summarization, and analysis of data as well as literature and database searches and retrieval. In addition, contractor staff creates and/or maintains databases to track information concerning NCI-sponsored clinical trials. The RaPID project focuses on implementing and evaluating a re-engineered process to improve the timelines involved in activating NCI-sponsored Cooperative Group phase 3 trials, CTEP-held IND studies of all phases and investigator-initiated trials at NCI-designated Cancer Centers. Rationale for using other than fixed-price: <!-- /* Font Definitions */ @font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-alt:"Arial Rounded MT Bold"; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-1610611985 1073750139 0 0 159 0;} @font-face {font-family:Verdana; panose-1:2 11 6 4 3 5 4 4 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:536871559 0 0 0 415 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-parent:""; margin-top:0pt; margin-right:0pt; margin-bottom:10.0pt; margin-left:0pt; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:Calibri; mso-fareast-font-family:Calibri; mso-bidi-font-family:"Times New Roman";} @page Section1 {size:612.0pt 792.0pt; margin:72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.Section1 {page:Section1;} --> The complexity of the protocols varies due to the phase of the study, disease to be studied, drug(s) to be used and the statistical design of the trial. The uncertainties involved with the complexities of protocol development make it difficult to predict the amount of services required to support the clinical trials. Thus, uncertainties involved in contract performance do not permit costs to be estimated with sufficient accuracy to use any type of fixed price contract. As such, a cost reimbursement type action is appropriate.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/Awards/HHSN261200422005C-011.html)
- Record
- SN02106489-W 20100401/100330235015-561e0001012a78c55eb04c796fe049bb (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |